CClinicalTrials.gg
CompletedNCT06806124ETMEXCOVIDUpdated Feb 5, 2025

Impact of the Elevation Training Mask in CrossFit® Post-SARS-CoV-2 Infection.

An interventional study of Elevation Training Mask and Sham Elevation Training Mask in COVID19- Infection with SARS-CoV-2 Virus, SARS-CoV-2 Positive Patients and COVID-19 Pulmonary Complications, sponsored by University of Valladolid. Completed at 1 site in Spain. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by University of Valladolid · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2022, registered Jan 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Introduction: The Elevation Training Mask (ETM) could restore respiratory or hematological organic damages from the acute or post-infection phase of severe acute respiratory syndrome coronavirus 2 (SARSCoV2) because it would allow the application of hypoxia and respiratory muscle training during exercise. The aim of this study was to comparatively evaluate the respiratory and hematological parameters and performance of athletes who resume CrossFit® training using the ETM with respect to a control group (CG).

Material and methods: A single-blind randomized clinical trial, following the CONSORT ("Consolidated Standards of Reporting Trials") recommendations, 20 trained male athletes were randomly assigned to an experimental group (EG) using the ETM and to a CG using the simulated ETM, they completed 12 weeks of CrossFit® training after 1 month of the cessation of SARS-CoV-2 symptoms. Pre- and post-training tests included spirometric, hematological, and sports performance assessment.

02

Conditions studied

  • COVID19- Infection with SARS-CoV-2 Virus
  • SARS-CoV-2 Positive Patients
  • COVID-19 Pulmonary Complications
  • SARS-CoV-2 Infection (Symptomatic)

Keywords

  • Elevation Training Mask
  • SARS-CoV-2
  • CrossFit®
  • Spirometric Parameters
  • Hematological Biomarkers
  • WOD
03

In context

Infections

6,688 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 20 is below the median of 120 across 4,201 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

University of Valladolid is the lead sponsor of 31 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male aged 18 to 50 years.
  • Autonomy in training activities of CrossFit® programs, at least 1 month after the cessation of symptoms of SARS-CoV-2 infection -2 infection.
  • No hospitalization for COVID-19.
  • Autonomy in training activities of CrossFit® programs, at least 1 month after the cessation of symptoms of SARS-CoV-2 infection, to avoid residual effects of the disease and increase the safety of the athlete.
  • ≥20 months of experience training CrossFit®.
  • ≥2 participations in CrossFit® competitions in the last season.
  • Having completed Fran WODs ≤ 250 seconds before suffering from COVID-19. - Passing a complete pre-study medical examination to rule out pre-existing diseases or injuries, insisting particularly on the cardio-pulmonary examination.-- No consumption of illegal drugs according to the World Anti-Doping Agency (WADA) (stimulants, blood derivatives, anabolic) or take drugs (e.g. tramadol) or other ergogenic products.
  • Be informed about all possible risks or discomforts and benefits associated with the study and sign the informed consent form;.
  • Health sports insurance coverage.

Exclusion criteria

Exclusion Criteria:

  • Included any renal dysfunction, recent febrile illness, lower limb trauma or any history of muscle injury.
  • SARS-CoV-2 reinfection during the study.
  • Recent exposure to an altitude stimulus or hypoxia, except for the altitude of their usual residence (1063 m in Soria and 798 m in Salamanca).
  • Participants were also prevented to perform any intense physical activity outside the designed training protocol throughout the study and encouraged to follow the dietary instructions provided.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Elevation Training Mask (ETM) Group

    Elevation Training Mask (ETM) using the corresponding air restriction openings and filters. The first week, the additional altitude simulation was 914 m and the second, 1,829 m. These initial 2 weeks served to familiarize to the use of the ETM during training, as a process of acclimatization to the altitude simulation and airflow restriction. For the period between weeks 3 and 6 (both included) the simulated altitude was 2,743 m, and for weeks 7-12 (both included), the ETM was set to simulate 3,658 m altitude.

    Device: Elevation Training Mask

  • Sham comparator
    Control Group

    For the Control Group, the Elevation Training Mask (ETM) was used for 12 weeks with the largest openings available and without using the air restriction filters, so that there was little respiratory obstruction but the reduction in air flow was minimal, with the aim of having a simulated ETM treatment.

    Device: Sham Elevation Training Mask

Interventions

  • DeviceElevation Training Mask

    The Elevation Training Mask (ETM) 2.0 was used in all 36 training sessions over the 12 weeks of the study with progressive increases in air restriction to simulate altitude training. This methodology of using ETM during exercise was chosen following the study by Porcari et al. The first week, the additional altitude simulation was 914 m and in the second, 1,829 m. These initial 2 weeks served to adjust the use of the ETM during training, as a process of acclimatization to the altitude simulation and airflow restriction. For the period between weeks 3 and 6 (both inclusive) the simulated altitude was 2,743 m, and for weeks 7-12 (both inclusive), the ETM was set to simulate 3658 m altitude.

    Also known as: Experimental Group

  • DeviceSham Elevation Training Mask

    For the Control Group, the Elevation Training Mask (ETM) 2.0 was used for 12 weeks with the largest openings available and without using the air restriction filters, so that there was little respiratory obstruction and the reduction in air flow was minimal, with the aim of having a simulated ETM treatment

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. maximum inspiratory pressure (MIP)

    Maximal inspiratory pressure (MIP) evaluation in centimeters of water (cmH2O). MIP is a measure of the strength of inspiratory muscles, primarily the diaphragm, and allows for the assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength.

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  2. maximum expiratory pressure (MEP)

    Evaluation maximal expiratory pressure (MEP) aluation in centimeters of water (cmH2O). MEP measures the maximum positive pressure that can be generated from one expiratory effort starting from total lung capacity

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

Secondary outcomes

  1. forced vital capacity (FVC)

    Evaluation of Forced vital capacity (FVC) in Liters (L). FVC is a pulmonary function measurement that represents the total amount of air a person can forcibly exhale from their lungs after taking the deepest breath possible.

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  2. forced expiratory capacity in 1 second (FEV1)

    Evaluation of forced expiratory capacity in 1 second (FEV1) in Liters (L). FEV1 indicates the volume of air a person can forcefully exhale in one second.

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  3. maximum voluntary ventilation (MVV)

    Evaluation of Maximal Voluntary Ventilation (MVV) in Liters / minute (L/min). MVV is a measure of the maximum amount of air a person can breathe in and out within a specific time frame, typically one minute

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  4. vital capacity (VC)

    Evaluation of vital capacity (VC) in in Liters (L).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  5. red blood cells (RBC)

    Erythrocytes, red blood cells (RBC), are the functional components of blood responsible for transporting gases and nutrients throughout the human body. Evaluation of RBC million / microliter (mill/µL).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  6. Hemoglobin (Hb)

    Hemoglobin (Hb) is the protein molecule in red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the tissues back to the lungs. Hgb is made up of four protein molecules (globulin chains) that are connected. Evaluation of Hb in grams / deciliter (g/dL).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  7. hematocrit (Hct)

    A hematocrit test (Hct) is a simple blood test that measures the percentage of red blood cells in your blood. Evaluation of Hct in Percentage (%).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  8. reticulocytes (RET)

    Reticulocytes are immature red blood cells (RBCs) produced in the bone marrow and released into the peripheral blood, where they mature into RBCs within 1 to 2 days. Evaluation of Reticulocytes in Percentage (%).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  9. erythropoietin (EPO)

    Erythropoietin (EPO) is a hormone that regulates the production of red blood cells. It is produced by kidney cells in response to low oxygen levels in the tissues. EPO promotes the formation of red blood cells by the bone marrow. EPO deficiency can result in reduced production of red blood cells, leading to anemia. EPO is also known as eritropoyetina or hemopoyetina. Evaluation of EPO in milliunits/milliliter (mU/mL).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

Other outcomes

  1. Fran WOD

    Work of the Day (WOD): Perform the 21 Thrusters and 21 Pull-Ups, then 15 Thrusters and 15 Pull-Ups, then 9 Thrusters and 9 Pull-Ups, as fast as possible. Evaluation of Fran WOD in seconds (s).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

  2. CrossFit® Total

    Work of the Day (WOD): Sum of the best of 3 attempts at each lift: Back Squat; Shoulder Press; Deadlift. Attempt each lift 3 times. The weight must increase after each successful attempt at each movement. The weight may not be decreased after the first attempt. A failed rep counts as an attempt. Take the Back Squat and Shoulder Press (aka: Strict Press) from the weight rack. Evaluation of CrossFit® Total in kilograms (Kg).

    Time frame: First day of study and after 12 weeks of Elevation Training Mask 2.0 use (end of study)]

07

Study locations

1 site
  • Department of Cell Biology, Genetics, Histology and Pharmacology of the University of Valladolid
    Soria, 42005, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06806124
Lead sponsor
University of Valladolid
Responsible party
Diego Fernández Lázaro (Professor and Researcher, University of Valladolid) — Principal investigator
First posted
Feb 3, 2025
Start date
Jan 6, 2022
Primary completion
Dec 22, 2022
Completion
Dec 30, 2023
Last update
Feb 5, 2025

Study contacts

Diego Fernández Lázaro, Vice Dean and Professor
principal investigator · Faculty of Health Sciences, University of Valladolid, Soria Campus (Spain)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion